Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36245
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Reagan J.L. | en |
dc.contributor.author | Olszewski A.J. | en |
dc.contributor.author | Fedele P. | en |
dc.contributor.author | Bibas M. | en |
dc.contributor.author | Grigoriadis G. | en |
dc.contributor.author | Gilbertson M. | en |
dc.contributor.author | Castillo J.J. | en |
dc.contributor.author | Guerrero-Garcia T. | en |
dc.contributor.author | Baldini F. | en |
dc.contributor.author | Tchernonog E. | en |
dc.contributor.author | Cartron G. | en |
dc.contributor.author | Ninkovic S. | en |
dc.contributor.author | Cwynarski K. | en |
dc.contributor.author | Dierickx D. | en |
dc.contributor.author | Tousseyn T. | en |
dc.contributor.author | Lansigan F. | en |
dc.contributor.author | Linnik Y. | en |
dc.contributor.author | Mogollon R. | en |
dc.contributor.author | Navarro J.-T. | en |
dc.date.accessioned | 2021-05-14T12:17:15Z | en |
dc.date.available | 2021-05-14T12:17:15Z | en |
dc.date.copyright | 2019 | en |
dc.date.created | 20190212 | en |
dc.date.issued | 2019-02-12 | en |
dc.identifier.citation | British Journal of Haematology. 184 (4) (pp 679-682), 2019. Date of Publication: Februaryy 2019. | en |
dc.identifier.issn | 0007-1048 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/36245 | en |
dc.language | en | en |
dc.publisher | Blackwell Publishing Ltd | en |
dc.relation.ispartof | British Journal of Haematology | en |
dc.title | Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. | en |
dc.type | Letter | en |
dc.type.studyortrial | Opinion, perspective or news | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/bjh.15156 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 29527667 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29527667] | en |
dc.identifier.source | 621209118 | en |
dc.identifier.institution | (Castillo) Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States (Guerrero-Garcia) Division of Hematology and Oncology, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, MA, United States (Baldini, Bibas) National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy (Tchernonog, Cartron) Department of Haematology, CHU Montpellier, Montpellier, France (Ninkovic, Cwynarski) Department of Haematology, UCLH London, London, United Kingdom (Dierickx, Tousseyn) Department of Haematology, University Hospitals Leuven, Leuven, Belgium (Lansigan, Linnik) Division of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, United States (Mogollon) Department of Medicine, Universidad San Martin de Porres, Lima, Peru (Navarro) Catalan Institute of Oncology, German Trias I Pujol Hospital, Badalona, Spain (Olszewski, Reagan) Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, United States (Fedele, Gilbertson, Grigoriadis) Monash Haematology, Monash Medical Centre, Monash University, Clayton, Australia | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | bortezomib chemotherapy plasmablastic lymphoma survival | en |
dc.identifier.authoremail | Castillo J.J.; jorgej_castillo@dfci.harvard.edu | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Letter | - |
crisitem.author.dept | Haematology | - |
crisitem.author.dept | Haematology | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.